Cargando…
Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?
Autores principales: | Hirano, Masaru, Yamada, Masanori, Tanaka, Toshiaki, Koue, Toshiko, Saito, Tomohisa, Higashimori, Mitsuo, Ochiai, Hisao, Yamamoto, Junichi, Yaguchi, Saori, Mita, Sachiko, Hara, Katsutoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299455/ https://www.ncbi.nlm.nih.gov/pubmed/34837487 http://dx.doi.org/10.1002/cpdd.1044 |
Ejemplares similares
-
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine
por: Azuma, Junichi, et al.
Publicado: (2011) -
Fermilab joins in global live Web cast
por: Polansek, Tom
Publicado: (2005) -
NeuroCOVID: it's time to join forces globally
por: Helbok, Raimund, et al.
Publicado: (2020) -
The Taiwan Tobacco and Liquor Corporation: To ‘join the ranks of global companies’
por: Eckhardt, Jappe, et al.
Publicado: (2017) -
Biometrics firms join global push for ‘standard’ Covid passports
Publicado: (2021)